XML 63 R27.htm IDEA: XBRL DOCUMENT v3.25.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2024
Income Taxes [Abstract]  
Schedule of Components of the Deferred Tax Assets and Liabilities Significant components of the Company’s deferred tax assets and liabilities at December 31, 2024 and 2023 are as follows:
(in thousands)  2024   2023 
Deferred tax assets:        
Net operating losses carry forward  $47,875   $41,698 
Deferred revenue   8,217    8,219 
Share-based compensation   1,572    1,512 
Research and development/orphan drug credits   23,296    20,509 
Capitalized research and development expenses   20,664    18,684 
Others   (11)   (57)
Less: valuation allowance   (101,613)   (90,565)
Deferred tax assets, net  $
-
   $
-
 
Schedule of U.S. Federal Statutory Rates

The difference between the income tax provision and the amount that would result if the U.S. Federal statutory rates were applied to pre-tax losses for the year ended December 31, 2024 and 2023 are as follows:

 

(in thousands)  December 31,
2024
   December 31,
2023
 
                 
Federal statutory income taxes  $(8,031)   (21.0)%  $(10,252)   (21.0)%
State income taxes   (1,275)   (3.3)%   (1,743)   (3.6)%
Deferred true-up   259    0.7%   176    0.4%
Research and development/orphan drug tax credit   (2,787)   (7.3)%   (3,263)   (6.7)%
Other   788    2.0%   608    1.2%
Change in valuation allowance   11,046    28.9%   14,474    29.7%
Provision for income tax  $
-  
    
-  
   $
-  
    
-